Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Sunday, April 26

FDG PET Illustrates Hypometabolism in a Mouse Model of Alpha-Synucleinopathy (4142)

Kristina DeDuck, Elodie Brison, Simone P. Zehntner, Kelvin Luk, Barry J. Bedell
First published April 14, 2020,
Kristina DeDuck
1Biospective, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elodie Brison
1Biospective, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone P. Zehntner
1Biospective, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelvin Luk
2University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry J. Bedell
1Biospective, Inc.
3Research Institute of the McGill University Health Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
FDG PET Illustrates Hypometabolism in a Mouse Model of Alpha-Synucleinopathy (4142)
Kristina DeDuck, Elodie Brison, Simone P. Zehntner, Kelvin Luk, Barry J. Bedell
Neurology Apr 2020, 94 (15 Supplement) 4142;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Our aim was to assess in vivo metabolic changes using [18F]FDG PET imaging in transgenic mice following injection of α-synuclein pre-formed fibrils.

Background: Slowing intracerebral spread of α-synuclein pathology is a promising strategy to treat Parkinson’s disease and other synucleinopathies. The α-synuclein fibril inoculation model is a powerful preclinical tool for testing effectiveness of such potential disease-modifying treatments. Generally, this model has been well-characterized, but in vivo imaging data is limited. Understanding how pathological α-synuclein affects glucose metabolism via FDG PET imaging is valuable, as this non-invasive method is translatable to clinical studies.

Design/Methods: We injected α-synuclein pre-formed fibrils (PFFs) or control (PBS) into the anterior olfactory nucleus (AON) of M83 mice (containing human α-synuclein with the A53T mutation). We performed whole brain FDG PET imaging at 12 or 16 weeks post-injection (wpi). All scans were registered to a standard stereotaxic space for statistical analysis.

Results: Several regions showed hypometabolism in the injected vs. contralateral hemisphere in the PFF groups. At 12 wpi, ipsilateral olfactory regions were significantly reduced, and by 16 wpi, as pathology spread, piriform and isocortex were also significantly reduced. Control groups showed no hemispheric differences, confirming changes were not caused by the surgery. There were also clear group differences. At both timepoints, left and right olfactory regions were significantly lower in the PFF-injected group compared to the PBS group. Group average maps and voxelwise analysis further revealed more widespread hypometabolism in the PFF group, particularly at 16 wpi. This functional impairment complements other deficits in this model, including regional brain atrophy, neuronal loss, olfactory deficit, and sleep disturbances.

Conclusions: Injection of α-synuclein PFFs leads to metabolic changes measurable using FDG PET, and, in lieu of an in vivo measure of α-synuclein pathology, FDG PET is potentially a valuable, translatable tool for use in investigating treatments for PD and other synucleinopathies.

Disclosure: Dr. Deduck has nothing to disclose. Dr. Brison has nothing to disclose. Dr. Zehntner has nothing to disclose. Dr. Luk has received royalty, license fees, or contractual rights payments from Biospective, Psychogenics. Dr. Bedell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee: Biospective Inc.. Dr. Bedell holds stock and/or stock options in Stock: Biospective Inc. which sponsored research in which Dr. Bedell was involved as an investigator.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise